Bandingkan Harga & Kinerja Trimegah Bangun Persada Tbk. (NCKL) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Trimegah Bangun Persada Tbk. dan Organon Pharma Indonesia Tbk.: Trimegah Bangun Persada Tbk. diperdagangkan di Rp940 (kapitalisasi pasar 60,26 T, volume 24 jam 66,68 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Trimegah Bangun Persada Tbk. jauh lebih besar — sekitar 577,2× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| NCKL | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 60,26 T | 104,4 M |
Volume | 66,68 jt | — |
Lot | 666,76 rb | — |
Perputaran | 62,63 M | — |
Harga Rata-rata | 939,35 | — |
Nilai Transaksi | 62,63 M | — |
Harga Ekuilibrium Indikatif | 940 | — |
Volume Ekuilibrium Indikatif | 13,51 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Trimegah Bangun Persada Tbk.
PT Trimegah Bangun Persada Tbk. (the Company) was established in Indonesia based on Notarial Deed of Erna Priyono, S.H., No. 03 dated September 6, 2004.
Selengkapnya di halaman NCKL →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
